Results 51 to 60 of about 895 (178)

Antibiofilm activity of antifungal drugs, including the novel drug olorofim, against Lomentospora prolificans

Journal of Antimicrobial Chemotherapy, 2020
Abstract Objectives Patients with immunodeficiency or cystic fibrosis frequently suffer from respiratory fungal infections. In particular, biofilm-associated fungi cause refractory infection manifestations, linked to increased resistance to anti-infective agents.
Joerg Steinmann, Peter-Michael Rath, Jan Buer, Ann-Kathrin Weisner, Silke Dittmer, Lisa Kirchhoff   +5 more
openaire   +3 more sources

Hope on the horizon: Novel fungal treatments in development [PDF]

, 2020
The treatment of invasive fungal infections remains challenging due to limitations in currently available antifungal therapies including toxicity, interactions, restricted routes of administration, and drug resistance.
Coler-Reilly, Ariella, Larson, Lindsey, Rauseo, Adriana M, Spec, Andrej   +3 more
core   +1 more source

Advances in the Treatment of Invasive Fungal Disease [PDF]

, 2023
With over 300 million severe cases and 1.5 million deaths annually, invasive fungal diseases (IFDs) are a major medical burden and source of global morbidity and mortality.
An, Zhiqiang, Bills, Gerald F, Zhang, Zhuan   +2 more
core   +1 more source

Novel Promising Antifungal Target Proteins for Conquering Invasive Fungal Infections

Frontiers in Microbiology, 2022
Invasive fungal infections (IFIs) pose a serious clinical problem, but the antifungal arsenal is limited and has many disadvantages, such as drug resistance and toxicity.
Cheng Zhen, Hui Lu, Yuanying Jiang
doaj   +1 more source

Inhibition of azole-resistant Aspergillus fumigatus biofilm at various formation stages by antifungal drugs, including olorofim

Journal of Antimicrobial Chemotherapy, 2022
Abstract Objectives Interest in aspergillosis has increased over the past decades. An increase in the incidence of azole-resistant Aspergillus fumigatus strains has been reported; therefore, the need for novel therapeutic approaches is urgent.
Lisa Kirchhoff, Silke Dittmer, Dan-Tiberiu Furnica, Jan Buer, Eike Steinmann, Peter-Michael Rath, Joerg Steinmann   +6 more
openaire   +3 more sources

Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review

Journal of Fungi, 2022
The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals.
Rogelio de J. Treviño-Rangel, Gloria M. González, Alexandra M. Montoya, Olga C. Rojas, Mariana Elizondo-Zertuche, Neri A. Álvarez-Villalobos   +5 more
doaj   +1 more source

Endemic mycoses - are we making progress in management? [PDF]

, 2023
PURPOSE OF REVIEW: The endemic fungi are a significant cause of morbidity and mortality in effected patients. The range of endemicity for these are expanding with infections observed outside of traditional locations.
Bahr, Nathan, Thompson, George
core   +1 more source

Emerging Frontiers in Clinical Mycology: Innovations, Insights, and Impacts

Mycoses, Volume 69, Issue 1, January 2026.
ABSTRACT The Mycoses Study Group Education and Research Consortium (MSGERC)—a group comprising clinicians, researchers, patients, and industry partners—meets every 2 years to review the most significant challenges facing the clinical mycology community and plan research, education, and advocacy strategies to prevent fungal infections and improve ...
A. Apostolopoulou, A. G. Stewart, H. Yoon, J. M. Steinbrink, D. Z. P. Friedman, L. Ostrosky‐Zeichner, I. S. Schwartz, on behalf of the Mycoses Study Group Education and Research Consortium (MSGERC)   +7 more
wiley   +1 more source

Susceptibility Testing of Environmental and Clinical Aspergillus sydowii Demonstrates Potent Activity of Various Antifungals [PDF]

The genus Aspergillus consists of a vast number of medically and environmentally relevant species. Aspergillus species classified in series Versicolores are ubiquitous in the environment and include the opportunistic pathogen Aspergillus sydowii, which ...
de Groot, T., Hagen, F., Houbraken, J., Meijer, E.F.J., Meis, J.F., Rezusta, A., Spruijtenburg, B.   +6 more
core   +1 more source

Management of Invasive Pulmonary Aspergillosis in Intensive Care Units: Guidelines From the Fungal Infection Network of Switzerland (FUNGINOS)

Mycoses, Volume 68, Issue 11, November 2025.
ABSTRACT Invasive pulmonary aspergillosis (IPA) is increasingly recognised in intensive care units (ICU) affecting not only patients with classical immunosuppressive conditions but also other severely ill patients, including those with respiratory viral infections (influenza, COVID‐19), advanced chronic obstructive pulmonary disease or acute and ...
F. Lamoth, W. C. Albrich, S. Ragozzino, D. Bosetti, J. Delaloye, C. El Khoury, A. Munting, V. Portillo, I. Reinhold, J. Sumer, A. Zbinden, V. Bättig, C. Beigelman‐Aubry, K. Boggian, A. Conen, T. S. Fischer, C. Garzoni, D. Goldenberger, E. Hofmann, P. Khafagy, L. Kern, G. R. Kleger, C. Le Terrier, O. Marchetti, J. L. Pagani, N. J. Rupp, P. W. Schreiber, M. Siegemund, F. Kadgien, D. Neofytos, N. Khanna, on behalf of the Fungal Infection Network of Switzerland (FUNGINOS), Werner Albrich, Christoph Berger, Anne Bergeron, Sabina Berezowska, Pierre‐Yves Bochud, Katia Boggian, Anna Conen, Julie Delaloye, Stéphane Emonet, Véronique Erard, Christian Garzoni, Daniel Goldenberger, Vladimira Hinic, Cedric Hirzel, Eleftheria Evdokia Kampouri, Nina Khanna, Malte Kohns, Andreas Kronenberg, Frederic Lamoth, Basile Landis, Oscar Marchetti, Konrad Mühlethaler, Linda Müller, Dionysios Neofytos, Michael Osthoff, Jean‐Luc Pagani, Chantal Quiblier, Arnaud Riat, Niels Rupp, Bettina Schulthess, Peter Werner Schreiber, Martin Siegemund, Laura Walti   +64 more
wiley   +1 more source